AstraZeneca PLC Second Quarter and Half Year Results

Solid performance with sustained progress on the key priorities. -First half sales increased by 3 percent at constant exchange rates (CER). Core EPS increased by 3 percent at CER to $2.53. -Second quarter sales increased by 2 percent at CER. Core...